Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 6/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.66 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.66 |
| ▸ | TSHR | P16473 | 1/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.62 |
| ▸ | KCNA5 | P22460 | 4/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.62 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.62 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.59 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.59 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.59 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | MC4R | P32245 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4334322 | 1.00 | CYP1A2 (0.66) | CYP1A2CYP2C19CYP3A4CYP2D6TSHR | |
| SCHEMBL8916036 | 0.98 | CYP1A2 (0.62) | CYP1A2CYP2C19CYP3A4CYP2D6TSHR | |
| SCHEMBL1964502 | 0.98 | CYP1A2 (0.62) | CYP1A2CYP2C19CYP3A4CYP2D6TSHR | |
| SCHEMBL30364119 | 0.94 | OPRM1 (0.61) | CYP1A2CYP2C19CYP3A4CYP2D6TSHR | |
| SCHEMBL30363975 | 0.94 | OPRM1 (0.61) | CYP1A2CYP2C19CYP3A4CYP2D6TSHR | |
| SCHEMBL2962625 | 0.90 | OPRM1 (0.65) | CYP1A2CYP2C19CYP3A4CYP2D6TSHR | |
| SCHEMBL113896 | 0.85 | CYP1A2 (0.62) | CYP1A2CYP2C19CYP3A4CYP2D6TSHR | |
| SCHEMBL10601133 | 0.85 | CYP1A2 (0.62) | CYP1A2CYP2C19CYP3A4CYP2D6TSHR | |
| SCHEMBL3246700 | 0.83 | SLC6A4 (0.63) | CYP1A2CYP2C19CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL10598753 | 0.83 | OPRM1 (0.63) | CYP1A2CYP2C19CYP3A4CYP2D6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8637561-B2 | Linked diimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-8314135-B2 | Linked dibenzimidazole antivirals | ENANTA PHARMACEUTICALS, INC. (US) | 2012-11-20 | — | — | US | disclosed |
| US-8242156-B2 | Linked dibenzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2012-08-14 | — | — | US | disclosed |
| US-8188132-B2 | Linked dibenzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-20120076756-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2012-03-29 | — | — | US | disclosed |
| US-20100266543-A1 | LINKED DIBENZIMIDAZOLE ANTIVIRALS | ENANTA PHARMACEUTICALS, INC. | 2010-10-21 | — | — | US | disclosed |
| US-20100260715-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2010-10-14 | — | — | US | disclosed |
| US-20100233122-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2010-09-16 | — | — | US | disclosed |
| US-20100226882-A1 | LINKED DIIMIDAZOLE ANTIVIRALS | ENANTA PHARMACEUTICALS, INC. | 2010-09-09 | — | — | US | disclosed |
| US-20100226883-A1 | LINKED DIIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2010-09-09 | — | — | US | disclosed |
| US-20100221214-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2010-09-02 | — | — | US | disclosed |
| US-20100221215-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100226882-A1 | LINKED DIIMIDAZOLE ANTIVIRALS | EIF2AK2, ZC3HAV1, MAVS | CYP1A2 149/4885CYP2C19 190/4885CYP3A4 71/4885 |
| US-20120076756-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | EIF2AK2, ZC3HAV1, HAVCR2 | CYP1A2 175/4885CYP2C19 180/4885CYP3A4 56/4885 |
| US-20100260715-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | CYP1A2 205/4885CYP2C19 418/4885CYP3A4 204/4885 |
| US-20100233122-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | EIF2AK2, ZC3HAV1, HAVCR2 | CYP1A2 175/4885CYP2C19 180/4885CYP3A4 56/4885 |
| US-20100221215-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | EIF2AK2, NSUN2, ZC3HAV1 | CYP1A2 390/4885CYP2C19 392/4885CYP3A4 138/4885 |
| US-20100226883-A1 | LINKED DIIMIDAZOLE DERIVATIVES | EIF2AK2, ZC3HAV1, HAVCR2 | CYP1A2 240/4885CYP2C19 431/4885CYP3A4 136/4885 |
| US-20100221214-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | EIF2AK2, NSUN2, ZC3HAV1 | CYP1A2 390/4885CYP2C19 392/4885CYP3A4 138/4885 |
| US-20100266543-A1 | LINKED DIBENZIMIDAZOLE ANTIVIRALS | EIF2AK2, ZC3HAV1, NSUN2 | CYP1A2 278/4885CYP2C19 210/4885CYP3A4 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.